These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12018459)

  • 41. New insights into protective humoral responses and HIV vaccines.
    Stamatatos L; Davis D
    AIDS; 2001; 15 Suppl 5():S105-15. PubMed ID: 11816158
    [No Abstract]   [Full Text] [Related]  

  • 42. Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.
    Buonaguro L; Visciano ML; Tornesello ML; Tagliamonte M; Biryahwaho B; Buonaguro FM
    J Virol; 2005 Jun; 79(11):7059-67. PubMed ID: 15890945
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles.
    Brand D; Lemiale F; Turbica I; Buzelay L; Brunet S; Barin F
    AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1369-77. PubMed ID: 9788678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Survivors Remorse: antibody-mediated protection against HIV-1.
    Lewis GK; Pazgier M; DeVico AL
    Immunol Rev; 2017 Jan; 275(1):271-284. PubMed ID: 28133809
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.
    Karlsson Hedestam GB; Fouchier RA; Phogat S; Burton DR; Sodroski J; Wyatt RT
    Nat Rev Microbiol; 2008 Feb; 6(2):143-55. PubMed ID: 18197170
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design.
    Srivastava IK; Ulmer JB; Barnett SW
    Expert Rev Vaccines; 2004 Aug; 3(4 Suppl):S33-52. PubMed ID: 15285704
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advances in HIV-1 Vaccine Development.
    Gao Y; McKay PF; Mann JFS
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systems serology for evaluation of HIV vaccine trials.
    Ackerman ME; Barouch DH; Alter G
    Immunol Rev; 2017 Jan; 275(1):262-270. PubMed ID: 28133810
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutralization of HIV-1 by antibody.
    Sattentau QJ
    Curr Opin Immunol; 1996 Aug; 8(4):540-5. PubMed ID: 8794008
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralizing antibodies against HIV -- back in the major leagues?
    Ferrantelli F; Ruprecht RM
    Curr Opin Immunol; 2002 Aug; 14(4):495-502. PubMed ID: 12088685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of neutralizing antibodies in prevention of HIV-1 infection: what can we learn from the mother-to-child transmission context?
    Braibant M; Barin F
    Retrovirology; 2013 Oct; 10():103. PubMed ID: 24099103
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Defining the protective antibody response for HIV-1.
    Mascola JR
    Curr Mol Med; 2003 May; 3(3):209-16. PubMed ID: 12699358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Broadening our view of protective antibody responses against HIV.
    Burke B; Barnett SW
    Curr HIV Res; 2007 Nov; 5(6):625-41. PubMed ID: 18045118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Designing synthetic vaccines for HIV.
    Fernández-Tejada A; Haynes BF; Danishefsky SJ
    Expert Rev Vaccines; 2015 Jun; 14(6):815-31. PubMed ID: 25824661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Passive and active antibody studies in primates to inform HIV vaccines.
    Hessell AJ; Malherbe DC; Haigwood NL
    Expert Rev Vaccines; 2018 Feb; 17(2):127-144. PubMed ID: 29307225
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.
    Poignard P; Sabbe R; Picchio GR; Wang M; Gulizia RJ; Katinger H; Parren PW; Mosier DE; Burton DR
    Immunity; 1999 Apr; 10(4):431-8. PubMed ID: 10229186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Antibodiome-Mapping the Humoral Immune Response to HIV.
    Butler AL; Fischinger S; Alter G
    Curr HIV/AIDS Rep; 2019 Apr; 16(2):169-179. PubMed ID: 30903381
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HIV pathogenesis and vaccine development.
    Johnson RP
    Top HIV Med; 2006; 14(1):8-15. PubMed ID: 16641522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).
    Vaine M; Lu S; Wang S
    BioDrugs; 2009; 23(3):137-53. PubMed ID: 19627166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.